Advances of the treatment of autoimmune disease through targeting interleukin-23

Xiaozhen He,Xiaowen Huang,Ting Wang,Qingguo Ruan
DOI: https://doi.org/10.3760/cma.j.issn.1673-4394.2018.06.016
2018-01-01
International Journal of Immunology
Abstract:Autoimmune disease(AD)is a condition arising from an abnormal immune response that at-tack the body's own tissues. Study showed that AD affects 5-10% of the world's population. Interleukin23(IL-23)was discovered in 2000,and is widely involved in the regulation of immune responses. Studies have shown that IL-23 plays a critical role in the promotion of the production and the maintenance of pathogenic Th17 cells. Since Th17 cells play a vital role during the development of AD,targeting IL-23-Th17 axis can be an effective strategy for the treatment of AD. During the recent years,IL-23 has become a promising target for the therapy of various types of AD such as autoimmune arthritis,psoriasis,etc.
What problem does this paper attempt to address?